|
|
 |
|
Viewing report
|
|
|
|
Osteoporosis - Novel Agents to Battle for Payer Acceptance
Datamonitor, July 2009, Pages: 375
Osteoporosis affects more than 159 million people aged over 50 years across the seven major markets. The condition continues to represent an attractive therapy area for large pharmaceutical companies due to its high prevalence and level of unmet need.
Several encouraging pipeline candidates, such as denosumab (Amgen) and odanacatib (Merck & Co) are nearing the market and are forecast to achieve sales of $3.7 billion in 2018. However, due to patent expiries of leading brands such as Actonel (risedronic acid, Procter & Gamble/ Sanofi-Aventis), Evista (raloxifene, Eli Lilly), future players will enter an increasingly competitive market and will therefore face significant challenges in gaining the approval of payers and prescribers
Scope of the report:
- Patient potential analysis across the seven major markets and BRIC nations (Brazil, Russia, India, and China).
- Analysis of global osteoporosis prescriptions from 20042008, split by geographical region, drug class, molecule, and brand.
- In depth profiles of key current osteoporosis brands including SWOT analyses and country-specific sales forecasts to 2018.
- R&D pipeline analysis with detailed profiles and forecasts of key agents, including Amgens denosumab and new selective estrogen receptor modulators.
Highlights of this title:
The osteoporosis seven major market value was $7.1 billion in 2008, 76.4% of the global market. Although between 2007 and 2008 the market declined due to generic penetration of the market leading brand Fosamax (alendronate, Merck & Co), the launch of new pipeline drugs will result in a significant market growth.
The launch of four pipeline selective estrogen receptor modulators (SERMs) between 2009 and 2012 will boost class sales across the seven major markets. However, the challenge for marketing companies is to convince prescribers in the EU, where uptake has historically been low, of the effect of SERMs in the wider patient group.
The largest growth driver of the osteoporosis market over the forecast period is expected to be Amgens denosumab, potentially the first monoclonal antibody to market. However, success will rely on a good long-term safety profile and price competitiveness, which are relative unknowns at this stage.
Key reasons to purchase this title:
- Understand current and future osteoporosis drug market dynamics
- Gain insight into the unmet needs of current osteoporosis treatment and to what extent pipeline drugs will address these issues
- Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2018 in the US, Japan, France, Germany, Italy, Spain, and the UK
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Pipeline Insight: Osteoporosis - Intermittent Dosing Drives Market Growth
Osteoporosis Therapeutics - Global Strategic Business Report
Commercial Insight: Osteoporosis and HRT - HRT is down for the count, but can osteoporosis players pick up the pieces?
Commercial Insight: Osteoporosis - Risk management and reformulation offer best defense against generic onslaught
Osteoporosis - The Science Of Compliance
Stakeholder Insight: Osteoporosis - Generic Alendronate Further Establishes Oral Bisphosphonates as Gold Standard
Drugs of Tomorrow: Osteoporosis - Will Bone Building Drugs Revolutionize the Market?
Osteoporosis Market Forecast
Pipeline Insight: Osteoporosis - Intermittent Dosing and Multiple Indications Drive Market Growth
Commercial Insight: Osteoporosis and HRT - HRT is down for the count, but can osteoporosis players pick up the pieces?
Osteoporosis Therapeutics - A Global Market Perspective
Commercial Insight: Osteoporosis and HRT - Novel Osteoporosis Drugs Counter Generic Threat While HRT Players Regroup and Move Forward
|
|
|
|
